US 20260347460 A1: Methods for the treatment of thyroid eye disease

Case summary

The case is for application US 19/745,234. Its prior art date is 2022-11-23, the earliest priority date. It has 34 claims, as published, 2026-11-05. Claim 1 is independent. The claims have 10 features, by kind: SEQ ID (6), Identity (2) and CDR (2). The examiner rejected 1 more. The listing, “us20260347460a1-listing.xml”, holds 12 sequences: 10 protein sequences of 5 to 442 residues and 2 DNA sequences of 642 to 1,326 bases. Organisms, with how many sequences name each: Homo sapiens (12). The listing is the copy in a weekly full-text file, so it was not checked against WIPO ST.26. The claims recite SEQ ID NOs: 1-4 and 7-10. SEQ ID NO: 1 (protein, 442 residues, Homo sapiens) is recited in claims 2 and 3, and the description cites it in 2 paragraphs. SEQ ID NO: 2 (protein, 5 residues, Homo sapiens) is recited in claim 1, and the description cites it in 3 paragraphs. SEQ ID NO: 3 (protein, 16 residues, Homo sapiens) is recited in claim 1, and the description cites it in 3 paragraphs. SEQ ID NO: 4 (protein, 8 residues, Homo sapiens) is recited in claim 1, and the description cites it in 3 paragraphs. SEQ ID NO: 7 (protein, 214 residues, Homo sapiens) is recited in claims 2 and 3, and the description cites it in 2 paragraphs. Plan version 1, locked on 2026-11-23, has 2 groups: SEQ ID NOs: 2-4 and 8-10 on Patent proteins and Swiss-Prot (2 searches); SEQ ID NOs: 1 and 7 on Patent proteins and Swiss-Prot (2 searches). Every kept feature has a search. Plan version 1 ran: 4 of 4 search jobs done.

Filled in from template conductbiology.summaries.template.case.v1 b65b47e0. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.

Case	US 20260347460 A1: Methods for the treatment of thyroid eye disease
Case ID	`20500f16-8ae2-4ed5-ab87-3fecd22df8fe`
Started	2026-11-23 23:24 UTC by ConductScience
Application	US 19/745,234
Prior art date	2022-11-23 (earliest priority date)
Searches	4: 4 run from the plan, 0 added
Chosen results	5 publications and 0 matches kept
Notes	0
Case log	51 events; every event checks out
Last log event	Event 51, 2026-11-23 23:27 UTC
Last event SHA-256	`0754462163435ffb6e727a59b90d7a5c175eb841b0e9680eaf7d11e5f3ddb895`

Each search below names its record fingerprint: the SHA-256 that Sequences computed over the search record when the search finished. Opened in Sequences, the search shows the same value as recordSha256 under Search record. Any change to the record would change it.

Claims and plan

Claims	34 claims from US 20260347460 A1, imported 2026-11-23 23:24 UTC

Claims SHA-256	`daa4542e5a3e03d102e9a25e05fcb40615f56e550c86521bcebb39ab5041e69c`
Claim set	Set 1, as published, 2026-11-05, from US 20260347460 A1, publication XML
Features	11: 10 accepted, 1 rejected
Plan	Version 1, locked 2026-11-23 23:24 UTC, 4 searches
Plan SHA-256	`cbca2bce53c96979e57ad5e4239564fe6febddadf5aaf8c211ac666c266fa28f`
Plan follows	Set 1, as published, 2026-11-05, from US 20260347460 A1, publication XML, the current set
Its claims SHA-256	`daa4542e5a3e03d102e9a25e05fcb40615f56e550c86521bcebb39ab5041e69c`

The plan's searches

Plan version 1, locked 2026-11-23 23:24 UTC by ConductScience. Plan SHA-256 cbca2bce53c96979e57ad5e4239564fe6febddadf5aaf8c211ac666c266fa28f. Each search runs as written here.

The plan follows set 1, as published, 2026-11-05, from US 20260347460 A1, publication XML. Claims SHA-256 daa4542e5a3e03d102e9a25e05fcb40615f56e550c86521bcebb39ab5041e69c.

Search	Query	Method	Set	Thresholds	Reason
P1	SEQ ID NOs: 2 to 4, 8 to 10 from the listing	Automatic	Patent proteins, snapshot 2026-11-13-5e447c75c43f	Published before 2022-11-23	SEQ ID NOs: 2 to 4, 8 to 10, in claim 1: as written; CDRs.
P2	SEQ ID NOs: 1, 7 from the listing	Automatic	Patent proteins, snapshot 2026-11-13-5e447c75c43f	Identity 95% or more, published before 2022-11-23	SEQ ID NOs: 1, 7, in claims 2 and 3: 95% identity or more.
P3	SEQ ID NOs: 2 to 4, 8 to 10 from the listing	Automatic	Swiss-Prot, snapshot 2026-11-10-37cac4ca8f21	Published before 2022-11-23	SEQ ID NOs: 2 to 4, 8 to 10, in claim 1: as written; CDRs.
P4	SEQ ID NOs: 1, 7 from the listing	Automatic	Swiss-Prot, snapshot 2026-11-10-37cac4ca8f21	Identity 95% or more, published before 2022-11-23	SEQ ID NOs: 1, 7, in claims 2 and 3: 95% identity or more.

Features no search covered

Every kept feature had a search when this version was locked.

Notes

This case has no notes.

Searches

#	Search	In the case	Finished (UTC)	Matches	Kept
1	US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P1: SEQ ID NO: 2 to 4, 8 to 10	Plan 1, P1	2026-11-23 23:24	15,312	5

#	Search	In the case	Finished (UTC)	Matches	Kept
2	US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P2: SEQ ID NO: 1, 7	Plan 1, P2	2026-11-23 23:26	10,000	0
3	US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P3: SEQ ID NO: 2 to 4, 8 to 10	Plan 1, P3	2026-11-23 23:26	2,553	0
4	US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P4: SEQ ID NO: 1, 7	Plan 1, P4	2026-11-23 23:26	1,404	0

By applicant

The publications a reviewer kept, and the publications that hold each kept match, by the first applicant each publication names. Spellings that differ only in case, accents, punctuation or an ending such as Inc or GmbH share a row, as do names joined in the Applicants tab, with the joins in force when this report was made. Rows go by earliest date, then name, with Applicant not given last.

Applicant	Publications	Earliest	Searches
Medarex, Inc. (US)	WO 2009155180-A1, 2009-12-23	2009-12-23	1
Arvind Rajpal	US 20090317402-A1, 2009-12-24 US 20120202285-A1, 2012-08-09	2009-12-24	1
Pfizer Inc. and Bristol-Myers Squibb Company	US 8188235-B2, 2012-05-29 US 8436158-B2, 2013-05-07	2012-05-29	1

Summaries

Sequences filled in each summary below from a fixed template, with facts it read from this case. The examiner accepted each one as written, or edited it into their own words, and each row says which. Summaries the examiner rejected are not printed. The case log records every decision.

The results

The case's searches found 34,888 references. 13,244 of them meet the threshold of a claim feature. 23,144 of them were published before the prior art date, 2022-11-23. 5,696 more were filed before that date and published later. 1 of them has no publication date. The top references: WO 2009155180-A1 (rank 1, meets F2, F4, F6, F8, F9 and F10); P01601 (rank 2, meets F4); US 20090317402-A1 (rank 3, meets F2, F4, F6, F8, F9 and F10); P01611 (rank 4, meets F4); JP 2011524750-A (rank 5, meets F2, F4, F6, F8, F9 and F10). Every claim feature has a reference that meets its threshold. They come from searches 1 to 4 from the plan.

Filled in from template conductbiology.summaries.template.results.v1 91ed1f45. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.

What the description says about each claimed SEQ ID NO

SEQ ID NO	Summary	Filled in, then accepted by the examiner
SEQ ID NO: 1	SEQ ID NO: 1 is recited in claims 2 and 3. Claim 2 recites “at least 95% identity to SEQ ID NO: 1” (threshold 95%). Claim 3 recites “SEQ ID NO: 1” (threshold as written: identical over the full query). The description cites it in 2 paragraphs. Paragraph [0007]: “In some embodiments, the anti-IL-6 antibody or antibody fragment comprises a heavy chain polypeptide comprising a polypeptide having at least about 95% identity to SEQ ID NO: 1 and a light chain polypeptide comprising a polypeptide having at least about 95% identity to SEQ ID NO: 7.” Paragraph [0050]: “In some embodiments, said antibody or antibody fragment comprises a heavy chain polypeptide comprising a polypeptide having at least about 95%, about 96%, about 97%, about 98% or about 99% identity to SEQ ID NO: 1 and a light chain polypeptide comprising a polypeptide having at least about 95%, about 96%, about 97%, about 98% or about 99% identity to SEQ ID NO: 7.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.
SEQ ID NO: 2	SEQ ID NO: 2 is recited in claim 1. Claim 1 recites “CDRs as defined in SEQ ID NOs 2, 3 and 4” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0006]: “Provided herein is a method of treating thyroid eye disease (TED) comprising administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) complementarity-determining regions (CDRs) as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0050]: “Provided herein is a method of treating thyroid eye disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) CDRs as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0065]: “Provided herein is a pharmaceutical composition comprising (i) an anti-IL-6 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a VH domain and a VL domain, wherein: (a) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 2, HCDR2 of SEQ ID NO: 3 and HCDR3 of SEQ ID NO: 4; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 8, LCDR2 of SEQ ID NO: 9 and LCDR3 of SEQ ID NO: 10; and (ii) a pharmaceutically acceptable carrier, diluent or excipient.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.
SEQ ID NO: 3	SEQ ID NO: 3 is recited in claim 1. Claim 1 recites “CDRs as defined in SEQ ID NOs 2, 3 and 4” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0006]: “Provided herein is a method of treating thyroid eye disease (TED) comprising administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) complementarity-determining regions (CDRs) as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0050]: “Provided herein is a method of treating thyroid eye disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) CDRs as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0065]: “Provided herein is a pharmaceutical composition comprising (i) an anti-IL-6 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a VH domain and a VL domain, wherein: (a) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 2, HCDR2 of SEQ ID NO: 3 and HCDR3 of SEQ ID NO: 4; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 8, LCDR2 of SEQ ID NO: 9 and LCDR3 of SEQ ID NO: 10; and (ii) a pharmaceutically acceptable carrier, diluent or excipient.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.

SEQ ID NO	Summary	Filled in, then accepted by the examiner
SEQ ID NO: 4	SEQ ID NO: 4 is recited in claim 1. Claim 1 recites “CDRs as defined in SEQ ID NOs 2, 3 and 4” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0006]: “Provided herein is a method of treating thyroid eye disease (TED) comprising administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) complementarity-determining regions (CDRs) as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0050]: “Provided herein is a method of treating thyroid eye disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) CDRs as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0065]: “Provided herein is a pharmaceutical composition comprising (i) an anti-IL-6 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a VH domain and a VL domain, wherein: (a) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 2, HCDR2 of SEQ ID NO: 3 and HCDR3 of SEQ ID NO: 4; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 8, LCDR2 of SEQ ID NO: 9 and LCDR3 of SEQ ID NO: 10; and (ii) a pharmaceutically acceptable carrier, diluent or excipient.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.
SEQ ID NO: 7	SEQ ID NO: 7 is recited in claims 2 and 3. Claim 2 recites “at least 95% identity to SEQ ID NO: 7” (threshold 95%). Claim 3 recites “SEQ ID NO: 7” (threshold as written: identical over the full query). The description cites it in 2 paragraphs. Paragraph [0007]: “In some embodiments, the anti-IL-6 antibody or antibody fragment comprises a heavy chain polypeptide comprising a polypeptide having at least about 95% identity to SEQ ID NO: 1 and a light chain polypeptide comprising a polypeptide having at least about 95% identity to SEQ ID NO: 7.” Paragraph [0050]: “In some embodiments, said antibody or antibody fragment comprises a heavy chain polypeptide comprising a polypeptide having at least about 95%, about 96%, about 97%, about 98% or about 99% identity to SEQ ID NO: 1 and a light chain polypeptide comprising a polypeptide having at least about 95%, about 96%, about 97%, about 98% or about 99% identity to SEQ ID NO: 7.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.
SEQ ID NO: 8	SEQ ID NO: 8 is recited in claim 1. Claim 1 recites “CDRs as defined in SEQ ID NOs 8, 9 and 10” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0006]: “Provided herein is a method of treating thyroid eye disease (TED) comprising administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) complementarity-determining regions (CDRs) as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0050]: “Provided herein is a method of treating thyroid eye disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) CDRs as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0065]: “Provided herein is a pharmaceutical composition comprising (i) an anti-IL-6 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a VH domain and a VL domain, wherein: (a) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 2, HCDR2 of SEQ ID NO: 3 and HCDR3 of SEQ ID NO: 4; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 8, LCDR2 of SEQ ID NO: 9 and LCDR3 of SEQ ID NO: 10; and (ii) a pharmaceutically acceptable carrier, diluent or excipient.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.

SEQ ID NO	Summary	Filled in, then accepted by the examiner
SEQ ID NO: 9	SEQ ID NO: 9 is recited in claim 1. Claim 1 recites “CDRs as defined in SEQ ID NOs 8, 9 and 10” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0006]: “Provided herein is a method of treating thyroid eye disease (TED) comprising administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) complementarity-determining regions (CDRs) as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0050]: “Provided herein is a method of treating thyroid eye disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) CDRs as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0065]: “Provided herein is a pharmaceutical composition comprising (i) an anti-IL-6 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a VH domain and a VL domain, wherein: (a) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 2, HCDR2 of SEQ ID NO: 3 and HCDR3 of SEQ ID NO: 4; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 8, LCDR2 of SEQ ID NO: 9 and LCDR3 of SEQ ID NO: 10; and (ii) a pharmaceutically acceptable carrier, diluent or excipient.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.
SEQ ID NO: 10	SEQ ID NO: 10 is recited in claim 1. Claim 1 recites “CDRs as defined in SEQ ID NOs 8, 9 and 10” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph [0006]: “Provided herein is a method of treating thyroid eye disease (TED) comprising administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) complementarity-determining regions (CDRs) as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0050]: “Provided herein is a method of treating thyroid eye disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment having the variable heavy (VH) CDRs as defined in SEQ ID NOs 2, 3 and 4, and the variable light (VL) CDRs as defined in SEQ ID NOs 8, 9 and 10.” Paragraph [0065]: “Provided herein is a pharmaceutical composition comprising (i) an anti-IL-6 antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion comprises a VH domain and a VL domain, wherein: (a) the VH domain amino acid sequence comprises HCDR1 of SEQ ID NO: 2, HCDR2 of SEQ ID NO: 3 and HCDR3 of SEQ ID NO: 4; and the VL domain amino acid sequence comprises LCDR1 of SEQ ID NO: 8, LCDR2 of SEQ ID NO: 9 and LCDR3 of SEQ ID NO: 10; and (ii) a pharmaceutically acceptable carrier, diluent or excipient.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.

The searches

A search's summary describes what the search returned, before the examiner's marks. Each search's section below shows the marks.

Search	Summary	Filled in, then accepted by the examiner
Search 1	Search 1, “US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P1: SEQ ID NO: 2 to 4, 8 to 10”, came from plan version 1, search P1. Method: Automatic (Smith-Waterman). Data searched: Public patent sequences and US applications: Patent proteins, snapshot 2026-11-13-5e447c75c43f, sources to 2026-11-13. Filters: published before 2022-11-23. Engine settings: tool: ssearch36; query: protein. It ran 6 queries and returned 15,312 hits. For feature F2 of claim 1 (“CDRs as defined in SEQ ID NOs 2, 3 and 4”, threshold as written: identical over the full query), it found 8,279 references. The first 5 in rank order: WO 2009155180-A1, US 20090317402-A1, JP 2011524750-A, US 8188235-B2 and US 20120202285-A1. WO 2009155180-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2009-12-23, before the prior art date; Query Match 100.0%; E-value 9.70e-5. For feature F4 of claim 1 (“CDRs as defined in SEQ ID NOs 8, 9 and 10”, threshold as written: identical over the full query), it found 28,383 references. The first 5 in rank order: WO 0114424-A2, WO 0168860-A1, JP 2002500514-A, WO 0212500-A2 and WO 0212502-A2. WO 0114424-A2 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2001-03-01, before the prior art date; Query Match 100.0%; E-value 1.70e-1.	Filled in from template conductbiology.summaries.template.search.v1 6781e001. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.
Search 2	Search 2, “US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P2: SEQ ID NO: 1, 7”, came from plan version 1, search P2. Method: Automatic (Smith-Waterman). Data searched: Public patent sequences and US applications: Patent proteins, snapshot 2026-11-13-5e447c75c43f, sources to 2026-11-13. Filters: identity at least 95%; published before 2022-11-23. Engine settings: tool: ssearch36; query: protein. It ran 2 queries and returned 10,000 hits. For feature F6 of claim 2 (“at least 95% identity to SEQ ID NO: 1”, threshold 95%), it found 127 references. The first 5 in rank order: WO 2009155180-A1, US 20090317402-A1, JP 2011524750-A, US 8188235-B2 and US 20120202285-A1. WO 2009155180-A1 ranks first. Rank keys, in order: meets 95% (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2009-12-23, before the prior art date; Query Match 100.0%; E-value 3.10e-180. For feature F8 of claim 2 (“at least 95% identity to SEQ ID NO: 7”, threshold 95%), it found 4,332 references. The first 5 in rank order: WO 2009155180-A1, US 20090317402-A1, JP 2011524750-A, US 8188235-B2 and US 20120202285-A1. WO 2009155180-A1 ranks first. Rank keys, in order: meets 95% (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2009-12-23, before the prior art date; Query Match 100.0%; E-value 2.60e-53. For feature F9 of claim 3 (“SEQ ID NO: 1”, threshold as written: identical over the full query), it found 127 references. The first 5 in rank order: WO 2009155180-A1, US 20090317402-A1, JP 2011524750-A, US 8188235-B2 and US 20120202285-A1. WO 2009155180-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2009-12-23, before the prior art date; Query Match 100.0%; E-value 3.10e-180. For feature F10 of claim 3 (“SEQ ID NO: 7”, threshold as written: identical over the full query), it found 4,332 references. The first 5 in rank order: WO 2009155180-A1, US 20090317402-A1, JP 2011524750-A, US 8188235-B2 and US 20120202285-A1. WO 2009155180-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2009-12-23, before the prior art date; Query Match 100.0%; E-value 2.60e-53.	Filled in from template conductbiology.summaries.template.search.v1 6781e001. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.

Search	Summary	Filled in, then accepted by the examiner
Search 3	Search 3, “US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P3: SEQ ID NO: 2 to 4, 8 to 10”, came from plan version 1, search P3. Method: Automatic (Smith-Waterman). Data searched: Public sequences: UniProt 2026_04 and ENA ESTs: Swiss-Prot, snapshot 2026-11-10-37cac4ca8f21, sources to 2026-11-10. Filters: published before 2022-11-23. Engine settings: tool: ssearch36; query: protein. It ran 6 queries and returned 2,553 hits. For feature F2 of claim 1 (“CDRs as defined in SEQ ID NOs 2, 3 and 4”, threshold as written: identical over the full query), it found 1,393 references. The first 5 in rank order: Q1GYT7, Q3J8X9, Q4FQ43, Q1Q8A5 and A5WBW9. Q1GYT7 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2008-10-14, before the prior art date; Query Match 100.0%; E-value 8.10e+1. For feature F4 of claim 1 (“CDRs as defined in SEQ ID NOs 8, 9 and 10”, threshold as written: identical over the full query), it found 1,540 references. The first 5 in rank order: P01601, P01611, A0A0C4DH73, P01597 and P01599. P01601 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 1980, before the prior art date; Query Match 100.0%; E-value 7.50e-3.	Filled in from template conductbiology.summaries.template.search.v1 6781e001. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.
Search 4	Search 4, “US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P4: SEQ ID NO: 1, 7”, came from plan version 1, search P4. Method: Automatic (Smith-Waterman). Data searched: Public sequences: UniProt 2026_04 and ENA ESTs: Swiss-Prot, snapshot 2026-11-10-37cac4ca8f21, sources to 2026-11-10. Filters: identity at least 95%; published before 2022-11-23. Engine settings: tool: ssearch36; query: protein. It ran 2 queries and returned 1,404 hits. For feature F6 of claim 2 (“at least 95% identity to SEQ ID NO: 1”, threshold 95%), it found 2 references. In rank order: P01859 and P06331. P01859 ranks first. Rank keys, in order: below 95% (73.1% identity over the full query); coverage of the claimed region 73.3%; published 1969, before the prior art date; Query Match 73.3%; E-value 6.70e-192. For feature F8 of claim 2 (“at least 95% identity to SEQ ID NO: 7”, threshold 95%), it found 3 references. In rank order: P01834, P01601 and A0A0A0MT89. P01834 ranks first. Rank keys, in order: below 95% (50.0% identity over the full query); coverage of the claimed region 50.0%; published 1967, before the prior art date; Query Match 50.0%; E-value 3.80e-57. For feature F9 of claim 3 (“SEQ ID NO: 1”, threshold as written: identical over the full query), it found 2 references. In rank order: P01859 and P06331. P01859 ranks first. Rank keys, in order: not as written (73.1% identity over the full query); coverage of the claimed region 73.3%; published 1969, before the prior art date; Query Match 73.3%; E-value 6.70e-192. For feature F10 of claim 3 (“SEQ ID NO: 7”, threshold as written: identical over the full query), it found 3 references. In rank order: P01834, P01601 and A0A0A0MT89. P01834 ranks first. Rank keys, in order: not as written (50.0% identity over the full query); coverage of the claimed region 50.0%; published 1967, before the prior art date; Query Match 50.0%; E-value 3.80e-57.	Filled in from template conductbiology.summaries.template.search.v1 6781e001. Accepted by the examiner, ConductScience, 2026-11-23 23:27 UTC.

Claim charts

Each chart sets a claim's features against one reference. Fixed rules (claim charts 1.0.0) read each feature against the reference's best match in this case's searches: Met, Not met, or Not shown where the match does not show it. Where the examiner set an answer, the chart gives it with the rule's answer beside it and the examiner's note. The case log records every answer. In a patent's table, What the patent says quotes a US publication's own words on its matching SEQ ID NOs, word for word, with where each comes from, or says why there is no quote (fixed rules, quotes 1.0.0).

Claim 1 and WO 2009155180-A1

Antibodies to il-6 and their uses. Published 2009-12-23, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 2, 3 and 4	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 3 positions 1 to 16 align with positions 1 to 16 of its sequence. Its SEQ ID NOs: 3, 4, 5, 6, 7, 24, 28, 29, 32, 34, 37, 40, 41 and 46. Source: Row 6 of search 1, WO 2009155180-A1	Quotes come from the full text of US publications only.
CDRs as defined in SEQ ID NOs 8, 9 and 10	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 8 positions 1 to 11 align with positions 1 to 11 of its sequence. Its SEQ ID NOs: 14, 15, 16, 17, 18, 26, 43 and 47. Source: Row 5,009 of search 1, WO 2009155180-A1	Quotes come from the full text of US publications only.

Claim 1 and US 20090317402-A1

ANTIBODIES TO IL-6 AND THEIR USES. Published 2009-12-24, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 2, 3 and 4	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 3 positions 1 to 16 align with positions 1 to 16 of its sequence. Its SEQ ID NOs: 3, 4, 5, 6, 7, 24, 28, 29, 32, 34, 37, 40, 41 and 46. Source: Row 6 of search 1, US 20090317402-A1	Claim 1: “… portion thereof comprising a heavy chain variable (VH) domain amino acid sequence comprising a CDR1, CDR2, and CDR3 region selected from the group consisting of: a) a VH CDR1 as set forth in SEQ ID NO:5, a VH CDR2 as set forth in SEQ ID NO:6, and a VH CDR3 as set forth in SEQ ID NO:7; …” Claim 5: “… or antigen-binding portion thereof comprising a heavy chain variable (VH) domain amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:37 and SEQ ID NO:40 or differs from any one of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:37 and …” SEQ ID NO: 3 is named in claims 12 and 14 and in the text after [0238]. SEQ ID NO: 4 is named in claims 5 and 6. SEQ ID NO: 5 is named in claims 1 and 4.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 8, 9 and 10	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 8 positions 1 to 11 align with positions 1 to 11 of its sequence. Its SEQ ID NOs: 14, 15, 16, 17, 18, 26, 43 and 47. Source: Row 5,009 of search 1, US 20090317402-A1	Claim 2: “The isolated human antibody or antigen-binding portion according to claim 1 further comprising a light chain variable (VL) domain amino acid sequence comprising a VL CDR1 as set forth in SEQ ID NO:16, a VL CDR2 as set forth in SEQ ID NO:17, and a VL CDR3 as set forth in SEQ ID NO:18.” Claim 7: “… or antigen-binding portion thereof comprising a light chain variable (VL) domain amino acid sequence selected from the group consisting of SEQ ID NO:15 or differs from SEQ ID NO:15, by having a conservative amino acid substitution, or differs from SEQ ID NO:15, by having a germline amino acid …” SEQ ID NO: 14 is named in claims 13 and 14 and in the text after [0238]. SEQ ID NO: 15 is named in claims 7, 8 and 9. SEQ ID NO: 16 is named in claims 2, 3 and 4.

Claim 1 and US 8188235-B2

Antibodies to IL-6 and their uses. Published 2012-05-29, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 2, 3 and 4	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 3 positions 1 to 16 align with positions 1 to 16 of its sequence. Its SEQ ID NOs: 3, 4, 5, 6, 7, 24, 28, 29, 32, 34, 37, 40, 41 and 46. Source: Row 6 of search 1, US 8188235-B2	Claim 1: “… or antigen-binding portion thereof comprising a heavy chain variable (VH) domain amino acid sequence comprising the VH CDR1 as set forth in SEQ ID NO:5, the VH CDR2 as set forth in SEQ ID NO:6, and the VH CDR3 as set forth in SEQ ID NO:7, and comprising a light chain variable (VL) domain amino …” Claim 2: “… or antigen-binding portion thereof comprising the heavy chain variable (VH) domain amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:29, and SEQ ID NO:37, and further comprising the light chain variable (VL) domain amino acid sequence as set forth in SEQ ID NO:15; …” SEQ ID NO: 3 is named in claim 5 and in paragraph [0242]. SEQ ID NO: 4 is named in claim 2. SEQ ID NO: 5 is named in claim 1.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 8, 9 and 10	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 8 positions 1 to 11 align with positions 1 to 11 of its sequence. Its SEQ ID NOs: 14, 15, 16, 17, 18, 26, 43 and 47. Source: Row 5,009 of search 1, US 8188235-B2	Claim 1: "… the VH CDR2 as set forth in SEQ ID NO:6, and the VH CDR3 as set forth in SEQ ID NO:7, and comprising a light chain variable (VL) domain amino acid sequence comprising the VL CDR1 as set forth in SEQ ID NO:16, the VL CDR2 as set forth in SEQ ID NO:17, and the VL CDR3 as set forth in SEQ ID NO:18; …" Claim 2: "… or antigen-binding portion thereof comprising the heavy chain variable (VH) domain amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:29, and SEQ ID NO:37, and further comprising the light chain variable (VL) domain amino acid sequence as set forth in SEQ ID NO:15; …" SEQ ID NO: 14 is named in claim 5 and in paragraph [0242]. SEQ ID NO: 15 is named in claims 2 and 9. SEQ ID NO: 16 is named in claim 1.

Claim 1 and US 20120202285-A1

ANTIBODIES TO IL-6 AND THEIR USES. Published 2012-08-09, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 2, 3 and 4	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 3 positions 1 to 16 align with positions 1 to 16 of its sequence. Its SEQ ID NOs: 3, 4, 5, 6, 7, 24, 28, 29, 32, 34, 37, 40, 41 and 46. Source: Row 6 of search 1, US 20120202285-A1	Claim 29: "… wherein the heavy chain complementarity determining region (CDR) CDR1, CDR2, and CDR3 amino acid sequences of the antibody comprise SEQ ID NOs: 5, 6, and 7, respectively, and wherein the light chain CDR1, CDR2, and CDR3 amino acid sequences of the antibody comprise SEQ ID NOs: 16, 17, and 18, …" Claim 30: "The isolated nucleic acid molecule of claim 29, wherein said heavy chain comprises a variable domain amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 29, and 37, and wherein said light chain comprises a variable domain amino acid sequence of SEQ ID NO: 15." SEQ ID NO: 3 is named in claim 41 and in the text after [0237]. SEQ ID NO: 4 is named in claims 30 and 40. SEQ ID NO: 5 is named in claims 29 and 39.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 8, 9 and 10	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 8 positions 1 to 11 align with positions 1 to 11 of its sequence. Its SEQ ID NOs: 14, 15, 16, 17, 18, 26, 43 and 47. Source: Row 5,009 of search 1, US 20120202285-A1	Claim 29: "… the heavy chain complementarity determining region (CDR) CDR1, CDR2, and CDR3 amino acid sequences of the antibody comprise SEQ ID NOs: 5, 6, and 7, respectively, and wherein the light chain CDR1, CDR2, and CDR3 amino acid sequences of the antibody comprise SEQ ID NOs: 16, 17, and 18, respectively." Claim 30: "The isolated nucleic acid molecule of claim 29, wherein said heavy chain comprises a variable domain amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 29, and 37, and wherein said light chain comprises a variable domain amino acid sequence of SEQ ID NO: 15." SEQ ID NO: 14 is named in claim 50 and in the text after [0237]. SEQ ID NO: 15 is named in claims 30 and 49. SEQ ID NO: 16 is named in claims 29 and 48.

Claim 1 and US 8436158-B2

Antibodies to IL-6 and their uses. Published 2013-05-07, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 2, 3 and 4	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 3 positions 1 to 16 align with positions 1 to 16 of its sequence. Its SEQ ID NOs: 3, 4, 5, 6, 7, 24, 28, 29, 32, 34, 37, 40, 41 and 46. Source: Row 6 of search 1, US 8436158-B2	Claim 1: "… wherein the heavy chain complementarity determining region (CDR) CDR1, CDR2, and CDR3 amino acid sequences of the antibody comprise SEQ ID NOs: 5, 6, and 7, respectively, and wherein the light chain CDR1, CDR2, and CDR3 amino acid sequences of the antibody comprise SEQ ID NOs: 16, 17, and 18, …" Claim 2: "The isolated nucleic acid molecule of claim 1, wherein said heavy chain comprises a variable domain amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 29, and 37, and wherein said light chain comprises the variable domain amino acid sequence of SEQ ID NO: 15." SEQ ID NO: 3 is named in claim 13 and in paragraph [0242]. SEQ ID NO: 4 is named in claims 2 and 12. SEQ ID NO: 5 is named in claims 1, 11 and 20.

Claim feature	Answer	What the match shows	What the patent says
CDRs as defined in SEQ ID NOs 8, 9 and 10	Met	Meets as written: 100.0% identity over the full query. Matches 3 of 3 SEQ ID NOs. SEQ ID NO: 8 positions 1 to 11 align with positions 1 to 11 of its sequence. Its SEQ ID NOs: 14, 15, 16, 17, 18, 26, 43 and 47. Source: Row 5,009 of search 1, US 8436158-B2	Claim 1: “… the heavy chain complementarity determining region (CDR) CDR1, CDR2, and CDR3 amino acid sequences of the antibody comprise SEQ ID NOs: 5, 6, and 7, respectively, and wherein the light chain CDR1, CDR2, and CDR3 amino acid sequences of the antibody comprise SEQ ID NOs: 16, 17, and 18, respectively.” Claim 2: “The isolated nucleic acid molecule of claim 1, wherein said heavy chain comprises a variable domain amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 29, and 37, and wherein said light chain comprises the variable domain amino acid sequence of SEQ ID NO: 15.” SEQ ID NO: 14 is named in claim 24 and in paragraph [0244]. SEQ ID NO: 15 is named in claims 2 and 23. SEQ ID NO: 16 is named in claims 1, 11 and 20.

Search 1: US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P1: SEQ ID NO: 2 to 4, 8 to 10

Search ID	`89712471-59ee-43cc-bc27-abd0c2e3e74f`
In this case	Run from plan version 1, search P1, by ConductScience on 2026-11-23 23:24 UTC
Finished	2026-11-23 23:24 UTC
Data searched	Public patent sequences and US applications: Patent proteins (17,651,841 sequences, 2,420,942,521 letters)
Data version	Snapshot 2026-11-13-5e447c75c43f, set patent_prot, sources to 2026-11-13, no additions
Engine	FASTA 36.3.8i; Sequences search engine 0.21.0
Settings	engine: Automatic; tool: ssearch36; program: blastp; query: protein
Plan filters	The tables below show matches with published before 2022-11-23, as the plan set
Query fingerprint	`5b89c98778829bd9c6fe6264c437eab454db300e92f96fcdbb7b3fcb5b095728`
Record fingerprint	`e3dc3befd9549756e9325cc2b5ac340aa9ed0da1a2bc6675978bb07c480df551`

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a sample of scores it draws the same way on every run, so the same search on the same snapshot returns the same rows. These results do not establish patentability.

Queries

Query	Length	Matches	Listed	Limit reached
SEQ_ID_NO_2	5		5	No
SEQ_ID_NO_3	16		5,000	Yes
SEQ_ID_NO_4	8		3	No
SEQ_ID_NO_8	11		5,000	Yes
SEQ_ID_NO_9	7		304	No
SEQ_ID_NO_10	9		5,000	Yes

```
>SEQ_ID_NO_2  (5 letters)
      1  EYYWS

>SEQ_ID_NO_3  (16 letters)
      1  EIFHSGSTNY NPSLKS

>SEQ_ID_NO_4  (8 letters)
      1  EELDDFDI

>SEQ_ID_NO_8  (11 letters)
      1  RASQGISSWL A

>SEQ_ID_NO_9  (7 letters)
      1  AASSLQS

>SEQ_ID_NO_10  (9 letters)
      1  QQYKSYPRT
```

Chosen publications

Publication	Published	Filed	Applicant	Title	Best query match	Reason
WO 2009155180-A1	2009-12-23		Medarex, Inc. (US)	Antibodies to il-6 and their uses	100%	
US 20090317402-A1	2009-12-24	2009-06-09, priority 2008-06-18	Arvind Rajpal	ANTIBODIES TO IL-6 AND THEIR USES	100%	
US 8188235-B2	2012-05-29	2009-06-09, priority 2008-06-18	Pfizer Inc. and Bristol-Myers Squibb Company	Antibodies to IL-6 and their uses	100%	
US 20120202285-A1	2012-08-09	2012-04-24, priority 2008-06-18	Arvind Rajpal	ANTIBODIES TO IL-6 AND THEIR USES	100%	
US 8436158-B2	2013-05-07	2012-04-24, priority 2008-06-18	Pfizer Inc. and Bristol-Myers Squibb Company	Antibodies to IL-6 and their uses	100%	

Why each chosen publication counts

The sentences a reviewer accepted, or edited into their own words, for each kept publication. Each draft stated one stored fact, and the case log keeps every draft and decision.

Publication	Why it counts	Sources
WO 2009155180-A1	SEQ ID NO: 28 of WO 2009155180-A1 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%). Published 2009-12-23, before the earliest priority date of 2022-11-23.	Row 414 of this search; WO 2009155180-A1: https://patents.google.com/patent/WO2009155180A1
US 20090317402-A1	SEQ ID NO: 28 of US 20090317402-A1 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%). Published 2009-12-24, before the earliest priority date of 2022-11-23.	Row 414 of this search; US 20090317402-A1: https://patents.google.com/patent/US20090317402A1
US 8188235-B2	SEQ ID NO: 28 of US 8188235-B2 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%). Published 2012-05-29, before the earliest priority date of 2022-11-23.	Row 414 of this search; US 8188235-B2: https://patents.google.com/patent/US8188235B2
US 20120202285-A1	SEQ ID NO: 28 of US 20120202285-A1 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%). Published 2012-08-09, before the earliest priority date of 2022-11-23.	Row 414 of this search; US 20120202285-A1: https://patents.google.com/patent/US20120202285A1
US 8436158-B2	SEQ ID NO: 28 of US 8436158-B2 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%). Published 2013-05-07, before the earliest priority date of 2022-11-23.	Row 414 of this search; US 8436158-B2: https://patents.google.com/patent/US8436158B2

Top publications

The first 15 of 31,189 publications, by best query match.

Publication	Published	Filed	Applicant	Title	Best query match	Matches
US 5565354-A	1996-10-15			Production of human monoclonal antibodies specific for hepatitis B surface antigen	100%	1
JP 1997020798-A	1997-01-21	1995-07-11	ASAHI CHEM IND CO LTD	HUMAN ANTI-HBS ANTIBODY	100%	1
WO 9713844-A1	1997-04-17		CAMBRIDGE ANTIBODY TECH (GB)	SPECIFIC BINDING MEMBERS FOR HUMAN TRANSFORMING GROWTH FACTOR BETA; MATERIALS AND METHODS	100%	1
US 5648077-A	1997-07-15			Treatment of patients infected with hepatitis B virus with a human monoclonal antibody	100%	1
US 5661016-A	1997-08-26			Transgenic non-human animals capable of producing heterologous antibodies of various isotypes	100%	1
US 5814318-A	1998-09-29			Transgenic non-human animals for producing heterologous antibodies	100%	1
US 5872215-A	1999-02-16			Specific binding members, materials and methods	100%	3
EP 0945464-A1	1999-09-29		CAMBRIDGE ANTIBODY TECH (GB)	Specific binding members for human transforming growth factor beta; materials and methods	100%	1
JP 2000253878-A	2000-09-19	1999-03-09	NISSHINBO IND INC,MEIJI MILK PROD CO LTD	Human anti-HBs antibody	100%	1
WO 0109187-A2	2001-02-08		MEDAREX, INC. (US)	Human monoclonal antibodies to her2/neu	100%	4
WO 0114424-A2	2001-03-01		MEDAREX, INC. (US)	Human ctla-4 antibodies and their uses	100%	6
JP 2001505059-A	2001-04-17	1997-12-03, priority 1996-12-03	ABGENIX INC	Transgenic mammals having human IG loci including plural VH and VK regions and antibodies produced therefrom	100%	4
WO 0127279-A1	2001-04-19		Cambridge Antibody Technology (GB)	Human anti-adipocyte monoclonal antibodies and their use	100%	3
US 6235883-A	2001-05-22			Human monoclonal antibodies to epidermal growth factor receptor	100%	4
WO 0144300-A2	2001-06-21		Cambridge Antibody Technology Limited (GB)	Brain specific binding members	100%	3

Top matches

The first 25 of 12,784 matches, in the order the results list them.

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
6,115	SEQ_ID_NO_8	AAB42669.1	US 5565354-A	1996-10-15	100%	100%	100%	2
10,009	SEQ_ID_NO_9	AAT13239.1	JP 1997020798-A	1997-01-21	100%	100%	100%	91
6,027	SEQ_ID_NO_8	A62120.1	WO 9713844-A1	1997-04-17	100%	100%	100%	1.7
6,100	SEQ_ID_NO_8	AAB78925.1	US 5661016-A	1997-08-26	100%	100%	100%	1.8
5,952	SEQ_ID_NO_8	AAE06885.1	US 5872215-A	1999-02-16	100%	100%	100%	1.7
5,969	SEQ_ID_NO_8	AAE06887.1	US 5872215-A	1999-02-16	100%	100%	100%	1.7
5,263	SEQ_ID_NO_8	AEC31695.1	WO 0109187-A2	2001-02-08	100%	100%	100%	1.7
5,009	SEQ_ID_NO_8	AAR60450.1	WO 0114424-A2	2001-03-01	100%	100%	100%	0.17
5,084	SEQ_ID_NO_8	ABE17471.1	WO 0114424-A2	2001-03-01	100%	100%	100%	1.5
5,454	SEQ_ID_NO_8	ABE17472.1	WO 0114424-A2	2001-03-01	100%	100%	100%	1.7
10,307	SEQ_ID_NO_9	BD520534	JP 2001505059-A	2001-04-17	100%	100%	100%	960
5,938	SEQ_ID_NO_8	AX112559.1	WO 0127279-A1	2001-04-19	100%	100%	100%	1.7
6,059	SEQ_ID_NO_8	AX112695.1	WO 0127279-A1	2001-04-19	100%	100%	100%	1.7
6,065	SEQ_ID_NO_8	AX112523.1	WO 0127279-A1	2001-04-19	100%	100%	100%	1.7
10,310	SEQ_ID_NO_9	AAE72484.1	US 6235883-A	2001-05-22	100%	100%	100%	980
5,918	SEQ_ID_NO_8	AX167748.1	WO 0144300-A2	2001-06-21	100%	100%	100%	1.7
6,048	SEQ_ID_NO_8	AX167712.1	WO 0144300-A2	2001-06-21	100%	100%	100%	1.7
6,103	SEQ_ID_NO_8	AAE75468.1	US 6255458-A	2001-07-03	100%	100%	100%	1.8
5,411	SEQ_ID_NO_8	AFA68354.1	WO 2001062907-A	2001-08-30	100%	100%	100%	1.7
5,172	SEQ_ID_NO_8	ABN35211.1	WO 0168860-A1	2001-09-20	100%	100%	100%	1.7
10,191	SEQ_ID_NO_9	BD528950	JP 2001520397-A	2001-10-30	100%	100%	100%	720

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
10,192	SEQ_ID_NO_9	BD528982	JP 2001520397-A	2001-10-30	100%	100%	100%	720
10,193	SEQ_ID_NO_9	BD528986	JP 2001520397-A	2001-10-30	100%	100%	100%	720
10,194	SEQ_ID_NO_9	BD528967	JP 2001520397-A	2001-10-30	100%	100%	100%	720
10,195	SEQ_ID_NO_9	BD528979	JP 2001520397-A	2001-10-30	100%	100%	100%	720

Search 2: US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P2: SEQ ID NO: 1, 7

Search ID	`0d2d6332-0879-4abf-b363-39901a32acb5`
In this case	Run from plan version 1, search P2, by ConductScience on 2026-11-23 23:24 UTC
Finished	2026-11-23 23:26 UTC
Data searched	Public patent sequences and US applications: Patent proteins (17,651,841 sequences, 2,420,942,521 letters)
Data version	Snapshot 2026-11-13-5e447c75c43f, set patent_prot, sources to 2026-11-13, no additions
Engine	FASTA 36.3.8i; Sequences search engine 0.21.0
Settings	engine: Automatic; tool: ssearch36; program: blastp; query: protein
Plan filters	The tables below show matches with identity at least 95%, published before 2022-11-23, as the plan set
Query fingerprint	`238f4c6bdaeeb7f06faec4e1acf9a046e9349bf3755ac10e7a396e828d3709c4`
Record fingerprint	`1dd88f840a7748f688000d3432a49375ec973dab46dd324294ba24c4b72043a5`

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a sample of scores it draws the same way on every run, so the same search on the same snapshot returns the same rows. These results do not establish patentability.

Queries

Query	Length	Matches	Listed	Limit reached
SEQ_ID_NO_1	442		5,000	Yes
SEQ_ID_NO_7	214		5,000	Yes

```
>SEQ_ID_NO_1  (442 letters)
      1  QVQLQQWGAG LLKPSETLSL TCAIYGGSFR EYYWSWIRQP PGKGLEWIGE IFHSGSTNYN
     61  PSLKSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCAREEL DDFDIWGQGT MVTVSSASTK
    121  GPSVFPLAPC SRSTSESTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
    181  LSSVVTVPSS NFGTQTYTCN VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP
    241  KPKDTLMISR TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVSV
    301  LTVVHQDWLN GKEYKCKVSN KGLPAPIEKT ISKTKGQPRE PQVYTLPPSR EEMTKNQVSL
    361  TCLVKGFYPS DIAVEWESNG QPENNYKTTP PMLDSDGSFF LYSKLTVDKS RWQQGNVFSC
    421  SVMHEALHNH YTQKSLSLSP GK

>SEQ_ID_NO_7  (214 letters)
      1  DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA ASSLQSGVPS
     61  RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YKSYPRTFGQ GTKVEIKRTV AAPSVFIFPP
    121  SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
    181  LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
```

Top publications

The first 15 of 4,384 publications, by best query match.

Publication	Published	Filed	Applicant	Title	Best query match	Matches
WO 2009155180-A1	2009-12-23		Medarex, Inc. (US)	Antibodies to il-6 and their uses	100%	3

Publication	Published	Filed	Applicant	Title	Best query match	Matches
US 20090317402-A1	2009-12-24	2009-06-09, priority 2008-06-18	Arvind Rajpal	ANTIBODIES TO IL-6 AND THEIR USES	100%	3
JP 2011524750-A	2011-09-08	2009-06-10, priority 2008-06-18	Pfizer Inc,Medarex Inc	ANTIBODIES TO IL-6 AND THEIR USES	100%	3
US 8188235-B2	2012-05-29	2009-06-09, priority 2008-06-18	Pfizer Inc. and Bristol-Myers Squibb Company	Antibodies to IL-6 and their uses	100%	3
US 20120202285-A1	2012-08-09	2012-04-24, priority 2008-06-18	Arvind Rajpal	ANTIBODIES TO IL-6 AND THEIR USES	100%	3
US 8436158-B2	2013-05-07	2012-04-24, priority 2008-06-18	Pfizer Inc. and Bristol-Myers Squibb Company	Antibodies to IL-6 and their uses	100%	3
US 20130280266-A1	2013-10-24	2013-04-05, priority 2008-06-18	Arvind Rajpal	ANTIBODIES TO IL-6 AND THEIR USES	100%	3
US 8846037-B2	2014-09-30	2013-04-05, priority 2008-06-18	Pfizer Inc. and Bristol-Myers Squibb Company	Antibodies to IL-6 and their uses	100%	3
US 20150203574-A1	2015-07-23	2014-08-29, priority 2008-06-18	Pfizer Inc.	ANTIBODIES TO IL-6 AND THEIR USES	100%	3
JP 2015166366-A	2015-09-24	2015-05-07, priority 2009-06-09	Pfizer Inc,Medarex Inc	ANTIBODIES TO IL-6 AND THEIR USES	100%	3
US 20250011416-A1	2025-01-09	2024-09-18, priority 2022-11-11	Tourmaline Bio, Inc.	METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE	100%	2
US 20250011417-A1	2025-01-09	2024-09-18, priority 2022-11-23	Tourmaline Bio, Inc.	METHODS FOR THE TREATMENT OF THYROID EYE DISEASE	100%	2
WO 2025014832-A1	2025-01-16	2024-07-05, priority 2023-07-07	KRIYA THERAPEUTICS INC	PERIOCULAR DELIVERY OF AAV VECTORS FOR TREATING OPHTHALMIC PATHOLOGIES	100%	2
KR 1020250107839-A	2025-07-14		TOURMALINE BIO, INC	METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE	100%	2
EP 4615867-A1	2025-09-17	2023-11-07, priority 2022-11-11	TOURMALINE BIO INC	METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE	100%	2

Top matches

The first 25 of 691 matches, in the order the results list them.

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
1	SEQ_ID_NO_1	AFL64187.1	WO 2009155180-A1	2009-12-23	100%	100%	100%	3.1e-180
5,001	SEQ_ID_NO_7	AFL64176.1	WO 2009155180-A1	2009-12-23	100%	100%	100%	2.6e-53
2	SEQ_ID_NO_1	AFL64185.1	WO 2009155180-A1	2009-12-23	99.7%	99.5%	100%	1.3e-179
5,002	SEQ_ID_NO_7	EP20220862039_213.1	WO 2021173844-A1	2021-09-02	99.5%	99.5%	100%	4.9e-53
5,009	SEQ_ID_NO_7	AEC31681.1	WO 2007011941-A2	2007-01-25	99.3%	99.1%	100%	7.2e-53
5,013	SEQ_ID_NO_7	AEC31671.1	WO 2007011941-A2	2007-01-25	99.2%	99.1%	100%	8.2e-53
5,016	SEQ_ID_NO_7	ARH64057.1	US 20140302036-A1	2014-10-09	99.2%	99.1%	100%	9.6e-53
5,014	SEQ_ID_NO_7	EP20230199698_16.1	WO 2018064307-A2	2018-04-05	99.2%	99.1%	100%	8.7e-53
5,012	SEQ_ID_NO_7	MC503297	JP 2018516969-A	2018-06-28	99.2%	99.1%	100%	8.2e-53
5,017	SEQ_ID_NO_7	MP946205.1	EP 3755724-A1	2020-12-30	99.1%	99.1%	100%	9.9e-53
5,019	SEQ_ID_NO_7	AEC31676.1	WO 2007011941-A2	2007-01-25	98.9%	98.6%	100%	1.2e-52
5,020	SEQ_ID_NO_7	AOH74971.1	US 20150353637-A1	2015-12-10	98.9%	99.1%	100%	1.2e-52
5,018	SEQ_ID_NO_7	ATL10673.1	WO 2016081748-A2	2016-05-26	98.9%	99.1%	100%	1.2e-52
5,021	SEQ_ID_NO_7	MP665905.1	WO 2020102501-A1	2020-05-22	98.9%	99.1%	100%	1.2e-52
5,022	SEQ_ID_NO_7	LG867274	WO 2016145085-A2	2016-09-15	98.8%	98.6%	100%	1.4e-52
5,025	SEQ_ID_NO_7	AOI36453.1	US 20040248215-A1	2004-12-09	98.7%	98.6%	100%	1.6e-52
5,024	SEQ_ID_NO_7	EP20230866723_54.1	US 20190336615-A1	2019-11-07	98.7%	98.6%	100%	1.5e-52
5,047	SEQ_ID_NO_7	MP590473.1	US 20190336615-A1	2019-11-07	98.7%	98.6%	100%	2.6e-52
5,043	SEQ_ID_NO_7	EP20230866723_60.1	EP 4590717-A1	2025-07-30	98.7%	98.6%	100%	2.5e-52
5,044	SEQ_ID_NO_7	EP20230866723_52.1	EP 4590717-A1	2025-07-30	98.7%	98.6%	100%	2.5e-52
5,045	SEQ_ID_NO_7	EP20230866723_51.1	EP 4590717-A1	2025-07-30	98.7%	98.6%	100%	2.5e-52

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
5,046	SEQ_ID_NO_7	EP20230866723_61.1	EP 4590717-A1	2025-07-30	98.7%	98.6%	100%	2.5e-52
5,048	SEQ_ID_NO_7	EP20230866723_57.1	EP 4590717-A1	2025-07-30	98.7%	98.6%	100%	2.6e-52
5,049	SEQ_ID_NO_7	EP20230866723_56.1	EP 4590717-A1	2025-07-30	98.7%	98.6%	100%	2.6e-52
5,026	SEQ_ID_NO_7	ADL98102.1	US 20040023313-A1	2004-02-05	98.6%	98.6%	100%	1.8e-52

Search 3: US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P3: SEQ ID NO: 2 to 4, 8 to 10

Search ID	`9d5a22ef-568e-4c69-a244-6b68e89b57ed`
In this case	Run from plan version 1, search P3, by ConductScience on 2026-11-23 23:24 UTC
Finished	2026-11-23 23:26 UTC
Data searched	Public sequences: UniProt 2026_04 and ENA ESTs: Swiss-Prot (487,796 sequences, 186,172,811 letters)
Data version	Snapshot 2026-11-10-37cac4ca8f21, set swissprot, sources to 2026-11-10, no additions
Engine	FASTA 36.3.8i; Sequences search engine 0.21.0
Settings	engine: Automatic; tool: ssearch36; program: blastp; query: protein
Plan filters	The tables below show matches with published before 2022-11-23, as the plan set
Query fingerprint	`5b89c98778829bd9c6fe6264c437eab454db300e92f96fcdbb7b3fcb5b095728`
Record fingerprint	`5c0270735c6d4de2144f23aba3f9f429be7ac60d21bd7fe2dc9b42e182f55189`

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a sample of scores it draws the same way on every run, so the same search on the same snapshot returns the same rows. These results do not establish patentability.

Queries

Query	Length	Matches	Listed	Limit reached
SEQ_ID_NO_2	5		221	No
SEQ_ID_NO_3	16		790	No
SEQ_ID_NO_4	8		194	No
SEQ_ID_NO_8	11		769	No
SEQ_ID_NO_9	7		169	No
SEQ_ID_NO_10	9		410	No

```
>SEQ_ID_NO_2  (5 letters)
      1  EYYWS

>SEQ_ID_NO_3  (16 letters)
      1  EIFHSGSTNY NPSLKS

>SEQ_ID_NO_4  (8 letters)
      1  EELDDFDI

>SEQ_ID_NO_8  (11 letters)
      1  RASQGISSWL A

>SEQ_ID_NO_9  (7 letters)
      1  AASSLQS

>SEQ_ID_NO_10  (9 letters)
      1  QQYKSYPRT
```

Top publications

All 3 publications, by best query match.

Publication	Published	Applicant	Title	Best query match	Matches
US 5356623	1994-10-18		Bacillus thuringiensis cryET1 toxin gene and protein toxic to lepidopteran insects.	100%	1
US 5589355	1996-12-31		Process for producing riboflavin.	56.4%	1
EP 3161140	2014-06-27		Cannabichromenic acid synthase from Cannabis sativa.	45.9%	1

Top matches

The first 25 of 2,548 matches, in the order the results list them.

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
1,979	SEQ_ID_NO_9	P01597		1970	100%	100%	100%	16
1,982	SEQ_ID_NO_9	P01599		1973	100%	100%	100%	16
1,206	SEQ_ID_NO_8	P01611		1980	100%	100%	100%	0.0075
1,207	SEQ_ID_NO_8	P01601		1980	100%	100%	100%	0.0075
1,977	SEQ_ID_NO_9	P01601		1980	100%	100%	100%	16
1,978	SEQ_ID_NO_9	P01611		1980	100%	100%	100%	16
110	SEQ_ID_NO_2	P0A370		1986	100%	100%	100%	540
1,981	SEQ_ID_NO_9	P04430		1986	100%	100%	100%	16
11	SEQ_ID_NO_2	P15893		1990	100%	100%	100%	160
113	SEQ_ID_NO_2	Q45716	US 5356623	1994-10-18	100%	100%	100%	550
93	SEQ_ID_NO_2	P96315		1997-05-01	100%	100%	100%	430
1,208	SEQ_ID_NO_8	A0A0C4DH73		2001	100%	100%	100%	0.0075
1,975	SEQ_ID_NO_9	A0A0C4DH72		2001	100%	100%	100%	16
1,976	SEQ_ID_NO_9	A0A075B6S4		2001	100%	100%	100%	16
1,980	SEQ_ID_NO_9	A0A0C4DH73		2001	100%	100%	100%	16

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
6	SEQ_ID_NO_2	Q6F7I0		2004	100%	100%	100%	86
5	SEQ_ID_NO_2	Q4FQ43		2005-08-30	100%	100%	100%	83
2	SEQ_ID_NO_2	Q3J8X9		2005-11-08	100%	100%	100%	82
4	SEQ_ID_NO_2	Q1Q8A5		2006-05-16	100%	100%	100%	83
3	SEQ_ID_NO_2	A5WBW9		2007-07-10	100%	100%	100%	83
9	SEQ_ID_NO_2	A6TGU9		2007-08-21	100%	100%	100%	140
8	SEQ_ID_NO_2	B5XXZ2		2008	100%	100%	100%	140
1	SEQ_ID_NO_2	Q1GYT7		2008-10-14	100%	100%	100%	81
1,983	SEQ_ID_NO_9	C5Y8Z8		2009	100%	100%	100%	76
222	SEQ_ID_NO_3	A0A075B6R2		2001	96.5%	93.8%	100%	1.5e-6

Search 4: US 20260347460 A1: Methods for the treatment of thyroid eye disease, plan 1 P4: SEQ ID NO: 1, 7

Search ID	`86914818-a409-40ce-ba91-49173327380c`
In this case	Run from plan version 1, search P4, by ConductScience on 2026-11-23 23:24 UTC
Finished	2026-11-23 23:26 UTC
Data searched	Public sequences: UniProt 2026_04 and ENA ESTs: Swiss-Prot (487,796 sequences, 186,172,811 letters)
Data version	Snapshot 2026-11-10-37cac4ca8f21, set swissprot, sources to 2026-11-10, no additions
Engine	FASTA 36.3.8i; Sequences search engine 0.21.0
Settings	engine: Automatic; tool: ssearch36; program: blastp; query: protein
Plan filters	The tables below show matches with identity at least 95%, published before 2022-11-23, as the plan set
Query fingerprint	`238f4c6bdaeeb7f06faec4e1acf9a046e9349bf3755ac10e7a396e828d3709c4`
Record fingerprint	`b410d5b725e2a98b192bfbbc879486cce2dc4f38674d497958dc95c044e2695e`

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a sample of scores it draws the same way on every run, so the same search on the same snapshot returns the same rows. These results do not establish patentability.

Queries

Query	Length	Matches	Listed	Limit reached
SEQ_ID_NO_1	442		627	No
SEQ_ID_NO_7	214		777	No

```
>SEQ_ID_NO_1  (442 letters)
      1  QVQLQQWGAG LLKPSETLSL TCAIYGGSFR EYYWSWIRQP PGKGLEWIGE IFHSGSTNYN
     61  PSLKSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCAREEL DDFDIWGQGT MVTVSSASTK
    121  GPSVFPLAPC SRSTSESTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
    181  LSSVVTVPSS NFGTQTYTCN VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP
    241  KPKDTLMISR TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVSV
    301  LTVVHQDWLN GKEYKCKVSN KGLPAPIEKT ISKTKGQPRE PQVYTLPPSR EEMTKNQVSL
    361  TCLVKGFYPS DIAVEWESNG QPENNYKTTP PMLDSDGSFF LYSKLTVDKS RWQQGNVFSC
    421  SVMHEALHNH YTQKSLSLSP GK

>SEQ_ID_NO_7  (214 letters)
      1  DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA ASSLQSGVPS
     61  RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YKSYPRTFGQ GTKVEIKRTV AAPSVFIFPP
    121  SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
    181  LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
```

Top publications

No publication matched.

Top matches

All 5 matches, in the order the results list them.

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
2	SEQ_ID_NO_1	P01859		1969	73.3%	99.7%	73.3%	6.7e-192
629	SEQ_ID_NO_7	P01834		1967	50%	100%	50%	3.8e-57
630	SEQ_ID_NO_7	P01601		1980	44%	98.9%	44.4%	2.4e-49
24	SEQ_ID_NO_1	P06331		1985	20.9%	95.9%	21.9%	5.7e-49
1,376	SEQ_ID_NO_7	A0A0A0MT89		2001	5.1%	100%	5.1%	6.4

Case log

51 events; every event checks out. Each event's SHA-256 covers the event and the SHA-256 of the one before it, so a change to any event breaks the chain from there on. The table shows each SHA-256's first 12 characters, in the events' words too.

#	When (UTC)	By	Event	SHA-256
1	2026-11-23 23:24	ConductScience	Started the case “US 20260347460 A1: Methods for the treatment of thyroid eye disease”.	`fbe53d4721b6`
2	2026-11-23 23:24	ConductScience	Imported 34 claims from US 20260347460 A1 as set 1 (as published, 2026-11-05). Claims SHA-256 daa4542e5a3e.	`5eff9e0d8d36`
3	2026-11-23 23:24	ConductScience	The rules (version 1.5.0) found 11 features.	`fc3243c351f2`
4	2026-11-23 23:24	ConductScience	Read 208 paragraphs of the description from US 20260347460 A1, 4 citing a SEQ ID NO. Specification SHA-256 75dd4ad45e3b.	`21a2df6042d3`
5	2026-11-23 23:24	ConductScience	Set the application number to US 19/745,234, from US 20260347460 A1.	`65af2c664278`
6	2026-11-23 23:24	ConductScience	Set the prior art date to 2026-07-17 (filing date), from US 20260347460 A1.	`de0b11165683`
7	2026-11-23 23:24	ConductScience	Set the prior art date to 2022-11-23 (earliest priority date).	`518c7e6fabce`
8	2026-11-23 23:24	ConductScience	Rejected F11 in claim 4 (CDR): “CDRs”. Note: Claim 4 refers back to the CDRs of claim 1, whose SEQ ID NOs are searched there.	`8d1b3c32bcbc`
9	2026-11-23 23:24	ConductScience	Accepted F1 in claim 1 (CDR): “CDRs”.	`31992b3c2f90`
10	2026-11-23 23:24	ConductScience	Accepted F2 in claim 1 (SEQ ID): “SEQ ID NOs 2, 3 and 4”.	`c27a13fbf183`
11	2026-11-23 23:24	ConductScience	Accepted F3 in claim 1 (CDR): “CDRs”.	`17ede2e7ed17`
12	2026-11-23 23:24	ConductScience	Accepted F4 in claim 1 (SEQ ID): “SEQ ID NOs 8, 9 and 10”.	`1dbe7b9be9b0`
13	2026-11-23 23:24	ConductScience	Accepted F5 in claim 2 (Identity): “at least 95% identity”.	`cbd5969ddff6`
14	2026-11-23 23:24	ConductScience	Accepted F6 in claim 2 (SEQ ID): “SEQ ID NO: 1”.	`557a89dc44f3`
15	2026-11-23 23:24	ConductScience	Accepted F7 in claim 2 (Identity): “at least 95% identity”.	`adf0d7ebcda6`
16	2026-11-23 23:24	ConductScience	Accepted F8 in claim 2 (SEQ ID): “SEQ ID NO: 7”.	`b6081b1901c1`
17	2026-11-23 23:24	ConductScience	Accepted F9 in claim 3 (SEQ ID): “SEQ ID NO: 1”.	`423f6616a8f9`
18	2026-11-23 23:24	ConductScience	Accepted F10 in claim 3 (SEQ ID): “SEQ ID NO: 7”.	`e0f3c2ada432`
19	2026-11-23 23:24	ConductScience	Drafted the plan: 4 searches, 0 features not covered.	`0769d8b3a71e`
20	2026-11-23 23:24	ConductScience	Locked plan version 1: 4 searches, 0 features not covered. Plan SHA-256 cbca2bce53c9.	`7ccb9f95ed4a`
21	2026-11-23 23:24	ConductScience	Ran P1, P2, P3 and P4 from plan version 1: 4 search jobs.	`be531a4861d4`
22	2026-11-23 23:26	ConductScience	Chose 5 references for the chart of claim 1.	`c414ee54932c`
23	2026-11-23 23:27	ConductScience	Kept publication WO 2009155180-A1 of search 89712471.	`c59a8a6d97fe`
24	2026-11-23 23:27	ConductScience	Kept publication US 20090317402-A1 of search 89712471.	`133efb3dd142`
25	2026-11-23 23:27	ConductScience	Kept publication US 8188235-B2 of search 89712471.	`299e3f0e5be6`
26	2026-11-23 23:27	ConductScience	Kept publication US 20120202285-A1 of search 89712471.	`90782613630f`
27	2026-11-23 23:27	ConductScience	Kept publication US 8436158-B2 of search 89712471.	`87498cf572cc`

#	When (UTC)	By	Event	SHA-256
28	2026-11-23 23:27	ConductScience	Accepted sentence 1 for publication WO 2009155180-A1 of search 89712471: “SEQ ID NO: 28 of WO 2009155180-A1 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%).”	`f4b35db8411b`
29	2026-11-23 23:27	ConductScience	Accepted sentence 3 for publication WO 2009155180-A1 of search 89712471: “Published 2009-12-23, before the earliest priority date of 2022-11-23.”	`fd2230181b4c`
30	2026-11-23 23:27	ConductScience	Accepted sentence 1 for publication US 20090317402-A1 of search 89712471: “SEQ ID NO: 28 of US 20090317402-A1 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%).”	`7a0ac5b395fb`
31	2026-11-23 23:27	ConductScience	Accepted sentence 3 for publication US 20090317402-A1 of search 89712471: “Published 2009-12-24, before the earliest priority date of 2022-11-23.”	`bf48cedd2335`
32	2026-11-23 23:27	ConductScience	Accepted sentence 1 for publication US 8188235-B2 of search 89712471: “SEQ ID NO: 28 of US 8188235-B2 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%).”	`cd0337af787d`
33	2026-11-23 23:27	ConductScience	Accepted sentence 3 for publication US 8188235-B2 of search 89712471: “Published 2012-05-29, before the earliest priority date of 2022-11-23.”	`e79811fc2102`
34	2026-11-23 23:27	ConductScience	Accepted sentence 1 for publication US 20120202285-A1 of search 89712471: “SEQ ID NO: 28 of US 20120202285-A1 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%).”	`9591d33cf409`
35	2026-11-23 23:27	ConductScience	Accepted sentence 3 for publication US 20120202285-A1 of search 89712471: “Published 2012-08-09, before the earliest priority date of 2022-11-23.”	`6399dc1f8c6e`
36	2026-11-23 23:27	ConductScience	Accepted sentence 1 for publication US 8436158-B2 of search 89712471: “SEQ ID NO: 28 of US 8436158-B2 matches SEQ ID NO: 3 of claim 1 at 100% identity over 16 of 16 residues (Query Match 100%).”	`6371cc88e8d2`
37	2026-11-23 23:27	ConductScience	Accepted sentence 3 for publication US 8436158-B2 of search 89712471: “Published 2013-05-07, before the earliest priority date of 2022-11-23.”	`405c521b42c8`
38	2026-11-23 23:27	ConductScience	Accepted the summary of the case, filled in from template conductbiology.summaries.template.case.v1 b65b47e0.	`779752335fc5`
39	2026-11-23 23:27	ConductScience	Accepted the summary of the results, filled in from template conductbiology.summaries.template.results.v1 91ed1f45.	`9c7a783408ae`
40	2026-11-23 23:27	ConductScience	Accepted the summary of search 1, filled in from template conductbiology.summaries.template.search.v1 6781e001.	`1b9cd1b11f85`
41	2026-11-23 23:27	ConductScience	Accepted the summary of search 2, filled in from template conductbiology.summaries.template.search.v1 6781e001.	`36cbbda395a1`
42	2026-11-23 23:27	ConductScience	Accepted the summary of search 3, filled in from template conductbiology.summaries.template.search.v1 6781e001.	`4af84f393b33`
43	2026-11-23 23:27	ConductScience	Accepted the summary of search 4, filled in from template conductbiology.summaries.template.search.v1 6781e001.	`fcee7c76499f`
44	2026-11-23 23:27	ConductScience	Accepted the summary of SEQ ID NO: 1, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`3669aa7b26a2`

#	When (UTC)	By	Event	SHA-256
45	2026-11-23 23:27	ConductScience	Accepted the summary of SEQ ID NO: 2, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`f4a97d518578`
46	2026-11-23 23:27	ConductScience	Accepted the summary of SEQ ID NO: 3, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`fb2c48f64e7e`
47	2026-11-23 23:27	ConductScience	Accepted the summary of SEQ ID NO: 4, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`a1b3c68354eb`
48	2026-11-23 23:27	ConductScience	Accepted the summary of SEQ ID NO: 7, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`470de8906669`
49	2026-11-23 23:27	ConductScience	Accepted the summary of SEQ ID NO: 8, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`2838c85d3221`
50	2026-11-23 23:27	ConductScience	Accepted the summary of SEQ ID NO: 9, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`5fad782b7f95`
51	2026-11-23 23:27	ConductScience	Accepted the summary of SEQ ID NO: 10, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`075446216343`